GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.

Submitted by admin on November 3, 2020 - 9:34pm
Source: 
BioSpace
News Tags: 
GW Pharma
cannabindoids
multiple sclerosis
spasticity
nabiximols
Sativex
Headline: 
GW Pharma Hopes to Bring Its Second Cannabis-Based Drug to Market in the U.S.
snippet: 

GW Pharmaceuticals hopes to bring its cannabis-based treatment for multiple sclerosis spasticity to the United States.

Do Not Allow Advertisers to Use My Personal information